NovaBridge Biosciences/$NBP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About NovaBridge Biosciences
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
Ticker
$NBP
Sector
Primary listing
Employees
30
Headquarters
Website
NBP Metrics
BasicAdvanced
$182m
-
-$0.92
1.74
-
Price and volume
Market cap
$182m
Beta
1.74
52-week high
$6.79
52-week low
$1.46
Average daily volume
730k
Financial strength
Current ratio
8.088
Quick ratio
7.906
Long term debt to equity
0.942
Total debt to equity
1.328
Profitability
EBITDA (TTM)
-94.201
Management effectiveness
Return on assets (TTM)
-24.90%
Return on equity (TTM)
-40.89%
Valuation
Price to book
0.78
Price to tangible book (TTM)
0.78
Price to free cash flow (TTM)
-7.297
Free cash flow yield (TTM)
-13.70%
Free cash flow per share (TTM)
-0.215
Growth
Earnings per share change (TTM)
236.90%
3-year earnings per share growth (CAGR)
-41.02%
What the Analysts think about NBP
Analyst ratings (Buy, Hold, Sell) for NovaBridge Biosciences stock.
NBP Financial Performance
Revenues and expenses
NBP Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs